主页 > 医学文档 >
【drug-news】山楂提取物可延长心衰病人寿命（s
Public release date: 27-Mar-2007
Herbal extract extends life for heart failure patients
Compound is shown to be safe; adds 4 months to patient survival
An herbal medicinal substance, Crataegus Extract WS?442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented today at the American College of Cardiology抯 56th Annual Scientific Session. Crataegus Extract WS?442 is an extract of leaves of the Crataegus tree, and is a natural antioxidant. The herb is currently approved for use in some European countries to treat early congestive heart failure, a condition in which the heart cannot pump enough blood to the body抯 other organs. ACC.07 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists to further breakthroughs in cardiovascular medicine.
The randomized, double-blind trial, known as the SPICE study, was conducted at 156 centers in Europe. The majority of the patients were male (84 percent) and nearly half the group (44 percent) were classified as NYHA III, meaning they were significantly impaired by their heart condition. The primary endpoint of the study was time to first cardiac event, including sudden cardiac death, death due to progressive heart failure, fatal heart attack, non-fatal heart attack or hospitalization due to heart failure.
A total of 2,681 patients with markedly impaired left ventricular function ?indicating advanced congestive heart failure ?were randomized to WS?442 or placebo for a duration of two years. All patients were already receiving pharmacological therapy with ACE-inhibitors (83 %), beta-blockers (64 %), glycosides (57 %), spironolactone (39 %) and diuretics (85 %).
Dr. Christian J. F. Holubarsch and his team saw a 20 percent reduction in cardiac-related deaths among patients on WS?442, extending patients?lives by four months during the first 18 months of the study. The safety of the compound was confirmed by a lower number of adverse events among the study group than those on placebo.
"WS 1442 is safe in patients with more severe congestive heart failure and left ventricular ejection fraction lower than 35 percent,?said Dr. Holubarsch of Median Kliniken Hospitals in Bad Krozingen, Germany, and lead study author. 揑t postpones death of cardiac cause after 18 months and sudden cardiac death in an important subgroup of patients."
Dr. Holubarsch wil present 揅rateagus Extract WS 1442 Postpones Cardiac Death in Patients With Congestive Heart Failure Class NYHA II-III: A Randomized, Placebo-Controlled, Double-Blind Trial in 2,681 Patients?on Tuesday, March 27 at 8:30 a.m. in Hall A. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 山楂提取物可延长心衰病人寿命
Public release date: 27-Mar-2007
发表日期：3007年3月27日
Herbal extract extends life for heart failure patients
题目：山楂提取物可延长心衰病人寿命
Compound is shown to be safe; adds 4 months to patient survival
An herbal medicinal substance, Crataegus Extract WS?442, safely extends the lives of
congestive heart failure patients already receiving pharmacological treatment for the
disease, according to a study presented today at the American College of Cardiology抯 56th Annual Scientific Session. Crataegus Extract WS?442 is an extract of leaves of the Crataegus tree, and is a natural antioxidant. The herb is currently approved for use in some European countries to treat early congestive heart failure, a condition in which the heart cannot pump enough blood to the body抯 other organs. ACC.07 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists to further breakthroughs in cardiovascular medicine.
（研究）显示该化合物是安全的，延长了心衰患者4个月的寿命。
今天在美国心脏病学会第56届年会上公布的一项研究结果显示：从山楂中提取的一种药用物质WS?442，安全地延长了已经接受过（其他）药物治疗的充血性心衰患者的生命。WS?442是从山楂树的树叶中提取出来的一种物质，它是一种天然的抗氧化剂。在一部分欧洲国家，目前已被批准用于治疗早期的充血性心衰，在这种情况下，心脏不能为机体的其他器官泵出足够的血液。ACC.07是最权威的心血管医学的会议，它集合了心脏病学家和心血管疾病专家们在心血管医学领域的更进一步的突破。
The randomized, double-blind trial, known as the SPICE study, was conducted at 156 centers in Europe. The majority of the patients were male (84 percent) and nearly half the group (44 percent) were classified as NYHA III, meaning they were significantly impaired by their heart condition. The primary endpoint of the study was time to first cardiac event, including sudden cardiac death, death due to progressive heart failure, fatal heart attack, non-fatal heart attack or hospitalization due to heart failure.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-29 17:14
医学,生命科学网